Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress. “As a physician, I know how important it is to provide patients with therapies that can be impactful across a broad population of individuals with NASH,